Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477581 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT00477581 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 102 participants.
The verdict
NCT00477581, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
This purpose of this study is to compare the effect of exenatide to that of sitagliptin on 2-hour postprandial glucose in subjects with type 2 diabetes mellitus.
Interventions
- DRUG exenatide
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477581
The ClinicalTrials.gov registry entry for NCT00477581 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exenatide is the first listed.
NCT00477581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477581 about?
NCT00477581 is a clinical study titled "A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus". This purpose of this study is to compare the effect of exenatide to that of sitagliptin on 2-hour postprandial glucose in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00477581?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2007-05. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00477581?
The interventions under investigation include: exenatide (DRUG), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00477581?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.